European Patent Office

T 0622/23 du 30.04.2025

Identifiant européen de la jurisprudence
ECLI:EP:BA:2025:T062223.20250430
Date de la décision
30 avril 2025
Numéro de l'affaire
T 0622/23
Requête en révision de
-
Numéro de la demande
11713597.0
Classe de la CIB
A61F 2/24
Langue de la procédure
Anglais
Distribution
Non distribuées (D)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
-
Titre de la demande
TRANSCATHETER PROSTHETIC HEART VALVE DELIVERY DEVICE WITH STABILITY TUBE
Nom du demandeur
Medtronic Inc.
Nom de l'opposant
Abbott Cardiovascular Systems, Inc.
Boston Scientific Corporation
Chambre
3.2.02
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 123(2)European Patent Convention Art 54(3)European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(2)
Mots-clés
Novelty - auxiliary request 3 (no)
Novelty - 5 (yes)
Inventive step - auxiliary request 5 (yes)
Sufficiency of disclosure - auxiliary request 5 (yes)
Amendments - added subject-matter
Amendments - auxiliary request 5 (no)
Amendment to case - reordering of requests (yes)
Amendment to case - admitted
(no) - auxiliary request 5 (no) - admitted (yes)
Exergue
-
Affaires citées
T 1192/22T 2564/22
Affaires citantes
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the Opposition Division with the order to maintain the patent in the following version:

- claims 1 to 6 of auxiliary request 5 as filed with the patent proprietor's statement setting out its grounds of appeal,

- description: paragraphs [0001] to [0009], [0011] to [0050] and [0052] to [0068] of the patent specification, paragraph [0010] as filed during the oral proceedings before the Opposition Division on 25 January 2023, and paragraph [0051] as filed during the oral proceedings before the Board on 30 April 2025, and

- the drawings of the patent specification.